Menu
MapConnectionsTopicsBulgariaThe Night (K-TRIO)Marie Skłodowska-CurieFor studentsFor teachersMethodologySurprise me
H2020Doctoral network2018–2022

ELBA · European Liquid Biopsies Academy - Towards widespread clinical application of blood- based diagnostic tools

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2018-01-01 → 2022-09-30
EU contribution
€3,727,723
Participants
21
Scheme
MSCA-ITN

Lines connect the coordinator with its partners.

Results in brief

European Liquid Biopsies Academy - Towards widespread clinical application of blood-based diagnostic tools

Liquid biopsies have been heralded as a game-changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialized in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mind-set with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatics proficiency. Currently, there are no comprehensive training programs to address this need. To move the promising liquid biopsy technology out of its infancy, the research program and educational curriculum of the European Liquid Biopsy Academy (ELBA) covers the entire value chain of diagnostics development and integrates all required disciplines and sectors. ELBA educates 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialization of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. ELBA focuses on the development of blood tests for early lung cancer detection and therapy selection.

Data: CORDIS, © European Union

Project objective

Liquid biopsies have been heralded as a game changer in cancer management, with blood tests offering a minimally invasive, safe, and sensitive alternative or complimentary approach for tissue biopsies. Blood represents a rich source of information through which solid cancers (and their subtypes) can be detected, identified and classified, and matched to a specific therapy. However, despite the potential of individual approaches, the promise of liquid biopsies has not yet materialised in the clinic. Widespread deployment requires creative next-generation researchers with an innovative mindset with access to a unique toolbox, including medical know-how, molecular diagnostics expertise (from health economics to regulatory), and statistical/bioinformatical proficiency. Currently, there are no comprehensive training programmes to address this need. To move the promising liquid biopsy technology out of its infancy, the research programme and educational curriculum of the European Liquid Biopsy Academy (ELBA) will cover the entire value chain of diagnostics development and integrate all required disciplines and sectors. ELBA will educate 15 Early Stage Researchers (ESRs) with the skills to circumvent the obstacles currently hampering effective development and commercialisation of liquid biopsy approaches. By creating a sustainable network to foster long-term multidisciplinary relationships and communication networks with various stakeholders we aim to accelerate clinical translation of these blood-based diagnostics. Most importantly, we have designed a well-balanced training programme to provide excellent career opportunities for the 15 ELBA ESRs. this includes training on state-of-the-art technologies and tools; bioinformatics, biostatistics and mathematical modelling; health economics and health technology assessment; diagnostic test development (including intellectual property and regulatory affairs); transferable skills (including leadership) and patient inclusion.

Original text from CORDIS.

Participants

  • STICHTING AMSTERDAM UMC · AmsterdamCoordinatorNetherlands
  • AVANIA BV · BILTHOVENNetherlands
  • CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER · MontpellierFrance
  • EUROPEAN CANCER PATIENT COALITION · Bruxelles / BrusselBelgium
  • EXOSOMICS SIENA SPA · SienaItaly
  • FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · LISBOAPortugal
  • GILUPI GMBH · PostdamGermany
  • GenomeScan B.V. · LeidenNetherlands
  • INSTITUT DE INVESTIGACIO EN CIENCIES DE LA SALUT GERMANS TRIAS I PUJOL · Badalona BarcelonaSpain
  • IZON SCIENCE LIMITED · OxfordUnited Kingdom
  • PANGAEA BIOTECH SL · BarcelonaSpain
  • PLOVDIVSKI UNIVERSITET PAISIY HILENDARSKI · PlovdivBulgaria
  • PNO Life Sciences & Health B.V. · RijswijkNetherlands
  • PRESIDENT AND FELLOWS OF HARVARD COLLEGE · CambridgeUnited States
  • Sense About Science · LondonUnknown Region
  • TATAA BIOCENTER AB · GOTEBORGSweden
  • UNIVERSIDAD DE GRANADA · GranadaSpain
  • UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF · HamburgGermany
  • UNIVERSITEIT TWENTE · EnschedeNetherlands
  • University of Padova · PaduaUnknown Region
  • V.O. Patents & Trademarks · MunichUnknown Region

Links

Data: CORDIS, © European Union